Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Any Condition Clear all
Completed No phase listed Observational

Registry Study for Talimogene Laherparepvec

NCT02173171
View directory record Official record
Conditions
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Interventions
Information collection
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Interventions
Ramucirumab, Atezolizumab, Peripheral blood draw, Biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134
View directory record Official record
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

NCT01039155
View directory record Official record
Conditions
Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 19, 2026, 10:27 PM EDT
Active, not recruiting Phase 1 Interventional

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686
View directory record Official record
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Healing Context in Complementary and Alternative Medicine (CAM): Instrument Development and Initial Validation

NCT01266304
View directory record Official record
Conditions
Any Condition
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 19, 2026, 10:27 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Lung Chemoemobolization

NCT05672108
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary, Endobronchial Metastases, Colon Cancer, Sarcoma
Interventions
Computed Tomography, Ethiodized Oil, Mitomycin, Transarterial Chemoembolization, Tris-acryl Gelatin Microspheres
Procedure · Drug · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 19, 2026, 10:27 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer

NCT01704885
View directory record Official record
Conditions
Any Cancer Diagnosis
Interventions
Play Intervention, Questionnaires
Behavioral · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
4 Years to 10 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Not applicable Interventional

ICanSTEP : Increasing Physical Activity With Text Messaging

NCT02627079
View directory record Official record
Conditions
A Diagnosis of Any Hematologic or Solid Malignancy
Interventions
Daily SMS text messaging
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

PD0332991/Paclitaxel in Advanced Breast Cancer

NCT01320592
View directory record Official record
Conditions
Breast Cancer
Interventions
PD0332991, Paclitaxel
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 19, 2026, 10:27 PM EDT
Completed No phase listed Observational

Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population

NCT00615147
View directory record Official record
Conditions
Cancer, Pulmonary Embolism
Interventions
CT pulmonary angiogram and d-dimer draw
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

NCT00003884
View directory record Official record
Conditions
Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
zoledronic acid, quality-of-life assessment
Drug · Procedure
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
55
States / cities
Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 19, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

Nudging and Relationship Building With Frequent Contact

NCT07104305
View directory record Official record
Conditions
Any Musculoskeletal Condition
Interventions
High-contact communication strategy
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Completed No phase listed Observational

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

NCT00612963
View directory record Official record
Conditions
Candidiasis, Oral, Thrush, Candidiasis
Interventions
Frio Oral Rinse
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 19, 2026, 10:27 PM EDT
Not listed Not applicable Interventional

Chronic Care Management for Adults at FQHCs

NCT02136732
View directory record Official record
Conditions
Any Condition in N73.0 Specified as Chronic
Interventions
Active self-management intervention, Attention control phone calls
Other
Lead sponsor
Washington State University
Other
Eligibility
45 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread

NCT01099631
View directory record Official record
Conditions
Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms, Biliary Cancer
Interventions
Salmonella typhimurium
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 19, 2026, 10:27 PM EDT
Recruiting Phase 2 Interventional

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

NCT04165772
View directory record Official record
Conditions
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Interventions
TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents

NCT00968552
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
Self-expandable stent placement via endoscopy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 19, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
lubiprostone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 19, 2026, 10:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 19, 2026, 10:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pulmonary Fibrosis Contact Registry

NCT01935726
View directory record Official record
Conditions
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 19, 2026, 10:27 PM EDT